BETA-2-ADRENORECEPTOR AGONIST, REDUCED RESPONSE TO
|
BLEEDING DISORDER, PLATELET-TYPE, 13, SUSCEPTIBILITY TO
|
BLEEDING DISORDER, PLATELET-TYPE, 8
|
BLUE CONE MONOCHROMACY
|
DIABETES INSIPIDUS, NEPHROGENIC, X-LINKED
|
DIABETES MELLITUS, TYPE 2, SUSCEPTIBILITY TO
|
FERTILE EUNUCH SYNDROME, INCLUDED
|
GLUCOCORTICOID DEFICIENCY 1
|
HIRSCHSPRUNG DISEASE, SUSCEPTIBILITY TO, 2
|
HUMAN IMMUNODEFICIENCY VIRUS TYPE 1, RESISTANCE TO
|
HYPERTHYROIDISM, NONAUTOIMMUNE
|
HYPOGONADOTROPIC HYPOGONADISM 11 WITHOUT ANOSMIA
|
HYPOGONADOTROPIC HYPOGONADISM 3 WITH ANOSMIA
|
HYPOGONADOTROPIC HYPOGONADISM 7 WITH ANOSMIA
|
HYPOGONADOTROPIC HYPOGONADISM 7 WITHOUT ANOSMIA
|
HYPOGONADOTROPIC HYPOGONADISM 8 WITH ANOSMIA, SUSCEPTIBILITY TO
|
HYPOGONADOTROPIC HYPOGONADISM 8 WITHOUT ANOSMIA
|
HYPOTHYROIDISM, CONGENITAL, NONGOITROUS, 1
|
HYPOTRICHOSIS 8
|
HYPOTRICHOSIS 8, INCLUDED
|
INCREASED ANALGESIA FROM KAPPA-OPIOID RECEPTOR AGONIST, FEMALE-SPECIFI
|
LEYDIG CELL ADENOMA, SOMATIC, WITH MALE-LIMITED PRECOCIOUS PUBERTY
|
LEYDIG CELL HYPOPLASIA, TYPE I
|
LEYDIG HYPOPLASIA, TYPE I
|
LUTEINIZING HORMONE RESISTANCE, FEMALE, INCLUDED
|
MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 5
|
MYOCLONUS-DYSTONIA SYNDROME
|
NEPHROGENIC SYNDROME OF INAPPROPRIATE ANTIDIURESIS
|
OBESITY
|
OBESITY, SUSCEPTIBILITY TO
|
OVARIAN DYSGENESIS 1
|
OVARIAN HYPERSTIMULATION SYNDROME
|
PRECOCIOUS PUBERTY, MALE-LIMITED
|
RENAL TUBULAR DYSGENESIS
|
RETINITIS PIGMENTOSA 44
|
SHORT STATURE, IDIOPATHIC, AUTOSOMAL
|
SKIN/HAIR/EYE PIGMENTATION 2, RED HAIR/FAIR SKIN
|
SOMATOSTATIN ANALOG, RESISTANCE TO
|
THYROID ADENOMA, HYPERFUNCTIONING, SOMATIC
|
THYROID ADENOMA, HYPERFUNCTIONING, SOMATIC, INCLUDED
|
THYROID CARCINOMA WITH THYROTOXICOSIS
|
UV-INDUCED SKIN DAMAGE, SUSCEPTIBILITY TO
|
WAARDENBURG SYNDROME, TYPE 4A
|
WAARDENBURG SYNDROME, TYPE 4A, INCLUDED
|
WOOLLY HAIR, AUTOSOMAL RECESSIVE 1
|
WOOLLY HAIR, AUTOSOMAL RECESSIVE 1, WITH OR WITHOUT HYPOTRICHOSIS
|